Kanichi Research Services, a UK developer of ultra-sensitive electrochemical sensors for the point of care healthcare market, has received £285k in a third funding.
This follow-on investment was made by The North West Fund for Biomedical, managed by SPARK Impact, which has now injected a total of £460k in the company.
Kanichi Research Services will use the funding to carry out an 18-month technical evaluation of its technology at St Mary’s Hospital in Manchester. The business is also relocating to the Biomedical Cluster at Liverpool Science Park as it plans to develop a handheld device for assessing chemicals in breath.
Kanichi is led by CEO David Killworth.